Výsledky vyhledávání - "Stephen Auerbach"

The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients

Autor: Adrian Wagg, David Castro-Diaz, Stephen Auerbach, Victor W. Nitti, Mary Beth Blauwet, Linda Cardozo, Emad Siddiqui

Publikováno v: Age and Ageing. 43:666-675

Introduction :m irabegron is aβ3-adrenoceptor agonist developed for the treatment of symptoms of overactive bladder (OAB). As the prevalence of OAB increases with age, a prospective subanalysis of individual and pooled efficacy and tolerability data

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d502b3be44847f9dd98401092b0c0c3
https://doi.org/10.1093/ageing/afu017

Zobrazit plný text záznamu

OnabotulinumtoxinA Improves Health-Related Quality of Life in Patients With Urinary Incontinence Due to Idiopathic Overactive Bladder: A 36-Week, Double-Blind, Placebo-Controlled, Randomized, Dose-Ranging Trial

Autor: Stephen Auerbach, David A. Ginsberg, J. Zhou, Vaishali Patel, Douglass S. Hale, Catherine Thompson, Clare J. Fowler, Piotr Radziszewski, Jonathan W. Kowalski, Tomasz Rechberger

Publikováno v: European Urology. 62:148-157

Background Patients with urgency urinary incontinence (UUI) due to overactive bladder (OAB) refractory to oral antimuscarinics have limited therapeutic options. OnabotulinumtoxinA appears to be an effective new treatment. Objective Assess disease-spe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a8ac280d893b38422077b42cd921e6a4
https://doi.org/10.1016/j.eururo.2012.03.005

Zobrazit plný text záznamu

Tadalafil 2.5 or 5 mg Administered Once Daily for 12 Weeks in Men with Both Erectile Dysfunction and Signs and Symptoms of Benign Prostatic Hyperplasia: Results of a Randomized, Placebo‐Controlled, Double‐Blind Study

Autor: Russell Blair Egerdie, Stephen Auerbach, Martin Sanchez Garza, Anne Esler, Pierre Costa, David G. Wong, Claus G. Roehrborn, Roberta J. Secrest

Publikováno v: The Journal of Sexual Medicine. 9:271-281

Introduction Erectile dysfunction (ED) and lower urinary tract symptoms suggestive of benign prostatic hyperplasia (BPH-LUTS) commonly coexist in aging men. Tadalafil, a phosphodiesterase type 5 inhibitor approved for treating ED, is currently being

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1426d132e9e2add5643697a705a267cd
https://doi.org/10.1111/j.1743-6109.2011.02504.x

Zobrazit plný text záznamu

Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment

Autor: Albert Elion-Mboussa, Jed C. Kaminetsky, Lars Viktrup, Claus G. Roehrborn, Stephen Auerbach, Rafael Martínez Montelongo

Publikováno v: BJU International. 105:502-507

Study Type – Therapy (RCT) Level of Evidence 1b OBJECTIVE To determine, by post hoc analysis, the effects of tadalafil (a long-acting phosphodiesterase 5 inhibitor) on peak urinary flow (Qmax), bladder capacity, voiding efficiency and the obstructi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b76b3e1b7fabc789b4bd2bce067e2a4
https://doi.org/10.1111/j.1464-410x.2009.08822.x

Zobrazit plný text záznamu

Vardenafil Restores Erectile Function to Normal Range in Men with Erectile Dysfunction

Autor: Harin Padma‐Nathan, Francesco Montorsi, François Giuliano, Eric Meuleman, Stephen Auerbach, Ian Eardley, Andrew McCullough, Martin Homering, Thomas Segerson, null for the North American and European Vardenafil Study Group

Publikováno v: The Journal of Sexual Medicine. 4:152-161

The ability of oral phosphodiesterase type 5 (PDE5) inhibitor therapy to restore erectile function to normal is an important attribute to men with erectile dysfunction (ED).To assess the ability of vardenafil to restore normal erectile function in me

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc553b7b7f8b411ed64f9afe0650df7c
https://doi.org/10.1111/j.1743-6109.2006.00380.x

Zobrazit plný text záznamu

Erectile response to vardenafil in men with a history of nonresponse to sildenafil: A time-from-dosing descriptive analysis

Autor: Culley C. Carson, Dimitrios Hatzichristou, Myron Murdock, Michael W. Colopy, H. Jeffrey Wilkins, Stephen Auerbach, Trish A. McBride, Philip Aliotta, Jack Barkin, Douglas Lording

Publikováno v: Clinical Therapeutics. 27:1452-1461

Background: The efficacy and tolerability of vardenafil hydrochloride in men with erectile dysfunction (ED) and a history of nonresponse to sildenafil citrate have previously been reported. Objective: The aim of this descriptive analysis was to asses

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6484c55c00572252e670840a4fe06eb
https://doi.org/10.1016/j.clinthera.2005.09.014

Zobrazit plný text záznamu

Safety and tolerability of the β3 -adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12-week randomised Phase III trials and of a 1-year randomised Phase III trial

Autor: Stephen Auerbach, Ian Milsom, Piotr Radziszewski, Christopher R. Chapple, Sender Herschorn, C. Walters, Victor W. Nitti, Mary Beth Blauwet

Publikováno v: International journal of clinical practice. 68(8)

SummaryAims To evaluate the safety and tolerability of the β3-adrenoceptor agonist, mirabegron, in patients with overactive bladder (OAB). Methods Tolerability and safety data from three 12-week, randomised, placebo-controlled, double-blind, Phase I

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fbca0611858d99f3593eba485243574a
https://pubmed.ncbi.nlm.nih.gov/24703195

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání